FDA approves Pfizer's RSV vaccine for adults at increased risk of …
Oct 22, 2024 · The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of...
Study reveals best timing for getting the RSV vaccine during …
1 day ago · Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly ...
CDC Updates RSV Vaccination Recommendation for Adults
Jun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone ages 75 and older receive the RSV vaccine.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way.
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged …
Oct 22, 2024 · FDA Approves Abrysvo (respiratory syncytial virus vaccine) for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults - May 31, 2023; Abrysvo (respiratory syncytial virus vaccine) FDA Approval History. More news resources. FDA Medwatch Drug Alerts; Daily MedNews; News for Health Professionals; New Drug Approvals; New Drug ...
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States.
Federal Officials Revise Recommendations for R.S.V. Vaccine
Jun 26, 2024 · The Food and Drug Administration has approved three R.S.V. vaccines. Two of them, GSK’s Arexvy and Pfizer’s Abrysvo, were approved in May last year and were administered during the fall and...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
Apr 9, 2024 · ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older
‘A good day’: FDA approves world’s first RSV vaccine - Nature
May 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain...